Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy: 2017-2018 to 2023 - ResearchAndMarkets.com

DUBLIN--()--The "Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's offering.

The key objectives of this study are to:

  • Review the historical development of CAR T-cell technology
  • Discuss the principles of chimeric antigen receptor design
  • Understand the mechanisms of action associated with CAR T-cell immunotherapy
  • Highlight the ongoing clinical and non-clinical advancements in the field of CAR T-cell therapy
  • Access the side effects, disadvantages and limitations of existing CAR T-cell technologies
  • Examine the current marketed drugs, including development activities and details of patent expirations
  • Determine the production methods for CAR T-cells
  • Review the range of joint ventures, collaborations, license and research agreements currently focused on CAR T-cell technology
  • Review of the regulatory requirements
  • Review the global CAR T-cell therapy market dynamics
  • Survey the key players involved in the development of therapeutics for CAR T-cell immunotherapy and provide company profiles

The report includes:

  • 31 data tables and 41 additional tables
  • An overview of the global market for current research & developments status of Chimeric Antigen Receptor (CAR) T-cell therapy
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Understand the market dynamics of CAR T-Cell therapy, along with the growth driving factors, restraints and future scope
  • Information on competitor initiatives, research and development status of CAR T-cell therapy
  • Comprehensive company profiles of major players in the market

Key Topics Covered

1 Introduction

2 Summary and Highlights

3 Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy

4 Current Production Methods, Latest Technological Advances and Future Direction

5 Clinical Trial Analysis of CAR T-Cells and Related Technologies

6 Incidence, Prevalence and Mortality Statistics for Cancer: A Global Summary

7 Global CAR T-Cell Market Analysis

8 Regulatory and Legislative Requirements for CAR T-Cell and Related Technologies

9 Patent Review/New Developments for Chimeric Antigen Receptors (CARs)

10 Company Profiles

  • Amgen
  • Avacta Life Sciences Ltd.
  • Bellicum Phamaceuticals
  • Bluebird Bio
  • Celgene Corp.
  • Cellectis
  • Celyad SA
  • Editas Medicine Inc.
  • Eureka Therapeutics Inc.
  • F. Hoffman La Roche AG
  • Formula Pharmaceuticals Inc.
  • Gilead Sciences
  • iCell Gene Therapeutics
  • Juno Therapeutics Inc. (A Celgene Company)
  • Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.)
  • Medimmune Llc/Astrazeneca
  • Mustang Bio Inc.
  • Noile-Immune Biotech
  • Novartis AG
  • Protheragen Inc.
  • Puretech Health
  • Servier Laboratories
  • Shire Pharmaceuticals Inc.
  • Takeda Pharmaceuticals
  • Transgene SA

For more information about this report visit https://www.researchandmarkets.com/research/w7xjsd/current_research?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Oncology Drugs